Overweight Nutritional, Metabolic, Endocrine Obesity
Conditions
Interventions
After this screening period, participants were randomly allocated to receive either the Phase 2® brand proprietary fractionated white bean extract or identical placebo in a double-blind manner. Assess
Sponsors
Pharmachem Laboratories
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged over 18 and under 40 at screening 2. Body Mass Index (BMI) more than or equal to 23kg/m^2 and less than 31 kg/m^2 at screening 3. Agreement to maintain diet, exercise and behavioral modification guidelines while participating in the study 4. Agreement to periodic follow-up 5. Females agreement to use appropriate birth control methods during the active study
Exclusion criteria
Exclusion criteria: 1. Use of any drugs, herbs or other non-prescription preparations for obesity within four weeks of screening including, but not limited to, Sibutramine, Orlistat, Phen-Fen, Metabolife, diuretics etc 2. Abnormal electrocardiogram (EKG), Complete Blood Count (CBC), metabolic panel, or physical examination 3. An active eating disorder 4. Severe hepatic or renal disease 5. History of seizure, alcohol abuse, chronic malabsorption, diverticulosis or diverticulitis 6. Diagnosis of coronary artery disease, congestive heart failure, stroke, arrhythmia, or uncontrolled hypertension 7. Pregnancy or lactation 8. Inability to understand or follow the study protocol 9. Diagnosis of significant psychiatric disease or depression 10. Known sensitivities to the product
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United States of America
Outcome results
None listed